JPWO2005112904A1 - ペルオキシソーム増殖剤応答性受容体（ｐｐａｒ）活性化剤、ならびにそれを用いた医薬、サプリメント、機能性食品および食品添加物 - Google Patents
ペルオキシソーム増殖剤応答性受容体（ｐｐａｒ）活性化剤、ならびにそれを用いた医薬、サプリメント、機能性食品および食品添加物 Download PDFInfo
- Publication number
- JPWO2005112904A1 JPWO2005112904A1 JP2006513743A JP2006513743A JPWO2005112904A1 JP WO2005112904 A1 JPWO2005112904 A1 JP WO2005112904A1 JP 2006513743 A JP2006513743 A JP 2006513743A JP 2006513743 A JP2006513743 A JP 2006513743A JP WO2005112904 A1 JPWO2005112904 A1 JP WO2005112904A1
- Authority
- JP
- Japan
- Prior art keywords
- cryptoxanthin
- ppar
- group
- mandarin
- insulin resistance
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000012190 activator Substances 0.000 title claims abstract description 42
- 239000013589 supplement Substances 0.000 title claims description 11
- 235000013373 food additive Nutrition 0.000 title claims description 10
- 239000002778 food additive Substances 0.000 title claims description 10
- 239000003814 drug Substances 0.000 title claims description 9
- 235000013376 functional food Nutrition 0.000 title claims description 9
- 239000003614 peroxisome proliferator Substances 0.000 title 1
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 claims abstract description 58
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 claims abstract description 58
- DMASLKHVQRHNES-UPOGUZCLSA-N (3R)-beta,beta-caroten-3-ol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C DMASLKHVQRHNES-UPOGUZCLSA-N 0.000 claims abstract description 45
- DMASLKHVQRHNES-ITUXNECMSA-N beta-cryptoxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CCCC2(C)C DMASLKHVQRHNES-ITUXNECMSA-N 0.000 claims abstract description 45
- 235000002360 beta-cryptoxanthin Nutrition 0.000 claims abstract description 45
- NBZANZVJRKXVBH-ITUXNECMSA-N all-trans-alpha-cryptoxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CCCC2(C)C)C NBZANZVJRKXVBH-ITUXNECMSA-N 0.000 claims abstract description 44
- 239000011774 beta-cryptoxanthin Substances 0.000 claims abstract description 44
- 235000020971 citrus fruits Nutrition 0.000 claims abstract description 24
- 241001672694 Citrus reticulata Species 0.000 claims abstract description 21
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 41
- 206010022489 Insulin Resistance Diseases 0.000 claims description 24
- 208000008589 Obesity Diseases 0.000 claims description 18
- 210000001789 adipocyte Anatomy 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 18
- 235000020824 obesity Nutrition 0.000 claims description 18
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 17
- 206010060378 Hyperinsulinaemia Diseases 0.000 claims description 17
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 17
- 206010020772 Hypertension Diseases 0.000 claims description 17
- 208000011775 arteriosclerosis disease Diseases 0.000 claims description 17
- 201000010099 disease Diseases 0.000 claims description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 17
- 230000003451 hyperinsulinaemic effect Effects 0.000 claims description 17
- 201000008980 hyperinsulinism Diseases 0.000 claims description 17
- 230000004069 differentiation Effects 0.000 claims description 7
- 210000005229 liver cell Anatomy 0.000 claims description 7
- 241000124008 Mammalia Species 0.000 claims description 6
- 230000006907 apoptotic process Effects 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 230000003213 activating effect Effects 0.000 claims description 4
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 claims 2
- 239000004212 Cryptoxanthin Substances 0.000 claims 1
- 235000019244 cryptoxanthin Nutrition 0.000 claims 1
- 229940075420 xanthine Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 11
- 235000013305 food Nutrition 0.000 abstract description 10
- 239000000796 flavoring agent Substances 0.000 abstract description 4
- 235000019634 flavors Nutrition 0.000 abstract description 4
- 230000009965 odorless effect Effects 0.000 abstract description 2
- 230000009967 tasteless effect Effects 0.000 abstract description 2
- 238000005119 centrifugation Methods 0.000 description 13
- 239000002244 precipitate Substances 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 8
- 239000003925 fat Substances 0.000 description 8
- 230000028327 secretion Effects 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 7
- 108010016731 PPAR gamma Proteins 0.000 description 7
- 102000000536 PPAR gamma Human genes 0.000 description 7
- 229940088598 enzyme Drugs 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 230000004913 activation Effects 0.000 description 6
- 235000021588 free fatty acids Nutrition 0.000 description 6
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 5
- 102000011690 Adiponectin Human genes 0.000 description 5
- 108010076365 Adiponectin Proteins 0.000 description 5
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 5
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 5
- 239000000654 additive Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 230000009471 action Effects 0.000 description 4
- 230000027455 binding Effects 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 230000003381 solubilizing effect Effects 0.000 description 4
- 235000008534 Capsicum annuum var annuum Nutrition 0.000 description 3
- 235000009467 Carica papaya Nutrition 0.000 description 3
- 241000207199 Citrus Species 0.000 description 3
- 244000061508 Eriobotrya japonica Species 0.000 description 3
- 235000009008 Eriobotrya japonica Nutrition 0.000 description 3
- 102100039556 Galectin-4 Human genes 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 101000608765 Homo sapiens Galectin-4 Proteins 0.000 description 3
- 108060001084 Luciferase Proteins 0.000 description 3
- 235000013399 edible fruits Nutrition 0.000 description 3
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 241000205585 Aquilegia canadensis Species 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 241000219172 Caricaceae Species 0.000 description 2
- 235000005976 Citrus sinensis Nutrition 0.000 description 2
- 240000002319 Citrus sinensis Species 0.000 description 2
- 235000011511 Diospyros Nutrition 0.000 description 2
- 241000723267 Diospyros Species 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 102000023984 PPAR alpha Human genes 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- -1 flakes Substances 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000003914 insulin secretion Effects 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 108020001756 ligand binding domains Proteins 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 108091008725 peroxisome proliferator-activated receptors alpha Proteins 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 238000010257 thawing Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- RDJGLLICXDHJDY-NSHDSACASA-N (2s)-2-(3-phenoxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-NSHDSACASA-N 0.000 description 1
- VHRUMKCAEVRUBK-WKELIDJCSA-N (z)-7-[(1s,5e)-5-[(z)-oct-2-enylidene]-4-oxocyclopent-2-en-1-yl]hept-5-enoic acid Chemical compound CCCCC\C=C/C=C1\[C@@H](C\C=C/CCCC(O)=O)C=CC1=O VHRUMKCAEVRUBK-WKELIDJCSA-N 0.000 description 1
- 102000007592 Apolipoproteins Human genes 0.000 description 1
- 108010071619 Apolipoproteins Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 240000004160 Capsicum annuum Species 0.000 description 1
- 235000007862 Capsicum baccatum Nutrition 0.000 description 1
- 240000006432 Carica papaya Species 0.000 description 1
- 108010059892 Cellulase Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000282552 Chlorocebus aethiops Species 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 241000555678 Citrus unshiu Species 0.000 description 1
- 240000000560 Citrus x paradisi Species 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 244000163122 Curcuma domestica Species 0.000 description 1
- 235000003392 Curcuma domestica Nutrition 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 101000741790 Homo sapiens Peroxisome proliferator-activated receptor gamma Proteins 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108010059820 Polygalacturonase Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- QTENRWWVYAAPBI-YZTFXSNBSA-N Streptomycin sulfate Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@H]1[C@H](N=C(N)N)[C@@H](O)[C@H](N=C(N)N)[C@@H](O)[C@@H]1O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@H]1[C@H](N=C(N)N)[C@@H](O)[C@H](N=C(N)N)[C@@H](O)[C@@H]1O QTENRWWVYAAPBI-YZTFXSNBSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 230000009858 acid secretion Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 150000001765 catechin Chemical class 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 229940106157 cellulase Drugs 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 235000003373 curcuma longa Nutrition 0.000 description 1
- 235000012754 curcumin Nutrition 0.000 description 1
- 239000004148 curcumin Substances 0.000 description 1
- 229940109262 curcumin Drugs 0.000 description 1
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 1
- 238000010864 dual luciferase reporter gene assay Methods 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 108010093305 exopolygalacturonase Proteins 0.000 description 1
- 229960001419 fenoprofen Drugs 0.000 description 1
- 229940125753 fibrate Drugs 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000020510 functional beverage Nutrition 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229940059442 hemicellulase Drugs 0.000 description 1
- 108010002430 hemicellulase Proteins 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- VNYSSYRCGWBHLG-AMOLWHMGSA-M leukotriene B4(1-) Chemical compound CCCCC\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC([O-])=O VNYSSYRCGWBHLG-AMOLWHMGSA-M 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 238000002803 maceration Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 150000002759 monoacylglycerols Chemical class 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 102000006255 nuclear receptors Human genes 0.000 description 1
- 108020004017 nuclear receptors Proteins 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 108010070456 protopectinase Proteins 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 235000021012 strawberries Nutrition 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 150000003548 thiazolidines Chemical class 0.000 description 1
- 235000013976 turmeric Nutrition 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Mycology (AREA)
- Botany (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Food Science & Technology (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Heart & Thoracic Surgery (AREA)
- Nutrition Science (AREA)
- Cardiology (AREA)
- Polymers & Plastics (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- General Preparation And Processing Of Foods (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2004150667 | 2004-05-20 | ||
| JP2004150667 | 2004-05-20 | ||
| JP2004242653 | 2004-08-23 | ||
| JP2004242653 | 2004-08-23 | ||
| PCT/JP2005/009258 WO2005112904A1 (ja) | 2004-05-20 | 2005-05-20 | ペルオキシソーム増殖剤応答性受容体（ppar）活性化剤、ならびにそれを用いた医薬、サプリメント、機能性食品および食品添加物 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012140693A Division JP2012214488A (ja) | 2004-05-20 | 2012-06-22 | ペルオキシソーム増殖剤応答性受容体（ｐｐａｒ）活性化剤、ならびにそれを用いた医薬、サプリメント、機能性食品および食品添加物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPWO2005112904A1 true JPWO2005112904A1 (ja) | 2008-03-27 |
Family
ID=35428235
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006513743A Pending JPWO2005112904A1 (ja) | 2004-05-20 | 2005-05-20 | ペルオキシソーム増殖剤応答性受容体（ｐｐａｒ）活性化剤、ならびにそれを用いた医薬、サプリメント、機能性食品および食品添加物 |
| JP2012140693A Pending JP2012214488A (ja) | 2004-05-20 | 2012-06-22 | ペルオキシソーム増殖剤応答性受容体（ｐｐａｒ）活性化剤、ならびにそれを用いた医薬、サプリメント、機能性食品および食品添加物 |
| JP2014073014A Pending JP2014122247A (ja) | 2004-05-20 | 2014-03-31 | ペルオキシソーム増殖剤応答性受容体（ｐｐａｒ）活性化剤、ならびにそれを用いた医薬、サプリメント、機能性食品および食品添加物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012140693A Pending JP2012214488A (ja) | 2004-05-20 | 2012-06-22 | ペルオキシソーム増殖剤応答性受容体（ｐｐａｒ）活性化剤、ならびにそれを用いた医薬、サプリメント、機能性食品および食品添加物 |
| JP2014073014A Pending JP2014122247A (ja) | 2004-05-20 | 2014-03-31 | ペルオキシソーム増殖剤応答性受容体（ｐｐａｒ）活性化剤、ならびにそれを用いた医薬、サプリメント、機能性食品および食品添加物 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20070218147A1 (https=) |
| EP (1) | EP1772143A4 (https=) |
| JP (3) | JPWO2005112904A1 (https=) |
| CN (1) | CN1956711B (https=) |
| WO (1) | WO2005112904A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007223914A (ja) * | 2006-02-21 | 2007-09-06 | Unitika Ltd | 経口投与組成物 |
| JP2007223979A (ja) * | 2006-02-24 | 2007-09-06 | Ehime Inryo:Kk | 肝臓脂質蓄積抑制剤 |
| JP5099617B2 (ja) * | 2006-03-16 | 2012-12-19 | 国立大学法人東京農工大学 | 歯周病予防・治療剤 |
| JP2008297216A (ja) * | 2007-05-29 | 2008-12-11 | Unitika Ltd | 繊維芽細胞増殖促進剤 |
| JP5356667B2 (ja) * | 2007-09-28 | 2013-12-04 | ユニチカ株式会社 | 体内時計正常化効果を有する組成物 |
| CN101909610B (zh) * | 2007-12-28 | 2013-12-04 | 尤尼蒂卡株式会社 | 口服给药组合物 |
| JP5830214B2 (ja) * | 2008-02-01 | 2015-12-09 | 株式会社ダイセル | 経口投与組成物 |
| JP5577019B2 (ja) * | 2007-12-28 | 2014-08-20 | ユニチカ株式会社 | 経口投与組成物 |
| JP2010202553A (ja) * | 2009-03-02 | 2010-09-16 | Unitika Ltd | レチノイン酸受容体（ｒａｒ）活性化剤 |
| JP2010254592A (ja) * | 2009-04-22 | 2010-11-11 | Ito En Ltd | 脂肪蓄積抑制剤及びそれを含有する飲食品 |
| JP5909084B2 (ja) | 2010-12-15 | 2016-04-26 | アークレイ株式会社 | 安定化βクリプトキサンチン含有水およびその用途 |
| JP2012206964A (ja) * | 2011-03-29 | 2012-10-25 | Unitika Ltd | ＰＰＡＲ−α活性調節剤 |
| CN103110846B (zh) | 2013-02-22 | 2014-07-02 | 嵊州市林美生物科技有限公司 | 一种用于治疗高脂血症的中药组合物及其制备方法和应用 |
| JP5925751B2 (ja) * | 2013-12-03 | 2016-05-25 | 株式会社ダイセル | 経口投与組成物 |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS50142750A (https=) * | 1974-05-10 | 1975-11-17 | ||
| JPH06165651A (ja) | 1991-02-01 | 1994-06-14 | Koopu Foods:Kk | 蜜柑麺の製造方法 |
| JP2000093086A (ja) | 1998-09-18 | 2000-04-04 | Haato & Haato:Kk | 蜜柑入り外郎及びその製造方法 |
| WO2000053563A1 (en) * | 1999-03-11 | 2000-09-14 | Nuclear Receptor Research Limited | Novel ligands of nuclear receptors ppar's |
| WO2001080854A1 (en) * | 2000-04-24 | 2001-11-01 | Nikken Chemicals Co., Ltd. | Activators for peroxisome proliferator-activated receptor |
| JP3359298B2 (ja) * | 1998-05-06 | 2002-12-24 | 株式会社愛媛柑橘資源開発研究所 | かんきつ果汁由来のカロチノイド高含有粉末の製造方法 |
| JP2004194512A (ja) * | 2002-12-16 | 2004-07-15 | Aritagawa:Kk | ミカン粉末、このミカン粉末を用いた餅菓子 |
| JP2004331528A (ja) * | 2003-05-02 | 2004-11-25 | Toyo Seikan Kaisha Ltd | 柿の果実からβ−クリプトキサンチン成分含有抽出物を製造する方法 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL129442A0 (en) * | 1999-04-14 | 2000-02-29 | Lycored Natural Prod Ind Ltd | Compounds useful in reducing the level of insulin like growth factor-1 (IGF-1) in blood |
-
2005
- 2005-05-20 EP EP05741624A patent/EP1772143A4/en not_active Ceased
- 2005-05-20 US US11/569,381 patent/US20070218147A1/en not_active Abandoned
- 2005-05-20 CN CN2005800160315A patent/CN1956711B/zh not_active Expired - Lifetime
- 2005-05-20 JP JP2006513743A patent/JPWO2005112904A1/ja active Pending
- 2005-05-20 WO PCT/JP2005/009258 patent/WO2005112904A1/ja not_active Ceased
-
2012
- 2012-06-22 JP JP2012140693A patent/JP2012214488A/ja active Pending
-
2014
- 2014-03-31 JP JP2014073014A patent/JP2014122247A/ja active Pending
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS50142750A (https=) * | 1974-05-10 | 1975-11-17 | ||
| JPH06165651A (ja) | 1991-02-01 | 1994-06-14 | Koopu Foods:Kk | 蜜柑麺の製造方法 |
| JP3359298B2 (ja) * | 1998-05-06 | 2002-12-24 | 株式会社愛媛柑橘資源開発研究所 | かんきつ果汁由来のカロチノイド高含有粉末の製造方法 |
| JP2000093086A (ja) | 1998-09-18 | 2000-04-04 | Haato & Haato:Kk | 蜜柑入り外郎及びその製造方法 |
| WO2000053563A1 (en) * | 1999-03-11 | 2000-09-14 | Nuclear Receptor Research Limited | Novel ligands of nuclear receptors ppar's |
| WO2001080854A1 (en) * | 2000-04-24 | 2001-11-01 | Nikken Chemicals Co., Ltd. | Activators for peroxisome proliferator-activated receptor |
| JP2004194512A (ja) * | 2002-12-16 | 2004-07-15 | Aritagawa:Kk | ミカン粉末、このミカン粉末を用いた餅菓子 |
| JP2004331528A (ja) * | 2003-05-02 | 2004-11-25 | Toyo Seikan Kaisha Ltd | 柿の果実からβ−クリプトキサンチン成分含有抽出物を製造する方法 |
Non-Patent Citations (8)
| Title |
|---|
| JPN6011055362; 食品工業 第４３巻，第１２号, 2000, 第２２-２６頁 * |
| JPN6011055363; ＦＥＢＳ Ｌｅｔｔｅｒｓ Ｖｏｌ．４４７, 1999, ｐ．１７-２０ * |
| JPN6011055364; Ｔｈｅ Ｌａｎｃｅｔ Ｖｏｌ．３４９, 1997, ｐ．９５２ * |
| JPN6012015177; Ｎｅｗ Ｆｏｏｄ ｉｎｄｕｓｔｒｙ ｐ．３０-３３, 1990 |
| JPN6014021089; 原一雄ら: '節約遺伝子と２型糖尿病' プラクティス Ｖｏｌ．１８／Ｎｏ．６, 2001, ｐ．６２３-６２６ |
| JPN7011002437; ＴＡＫＡＨＡＳＨＩ， Ｎ． ｅｔ ａｌ．: ＦＥＢＳ Ｌｅｔｔｅｒｓ Ｖｏｌ．５１４, 2002, ｐ．３１５-３２２ * |
| JPN7011002438; 杉浦実: 果実協会報 第５３３巻, 2003, 第３９-４６頁 * |
| JPN7011002439; ＭＯＮＴＯＮＥＮ， Ｊ． ｅｔ ａｌ．: Ｄｉａｄｅｔｅｓ ｃａｒｅ Ｖｏｌ．２７， Ｎｏ．２, 200402, ｐ．３６２-３６６ * |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2012214488A (ja) | 2012-11-08 |
| WO2005112904A1 (ja) | 2005-12-01 |
| EP1772143A1 (en) | 2007-04-11 |
| JP2014122247A (ja) | 2014-07-03 |
| CN1956711B (zh) | 2010-06-09 |
| US20070218147A1 (en) | 2007-09-20 |
| CN1956711A (zh) | 2007-05-02 |
| EP1772143A4 (en) | 2009-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014122247A (ja) | ペルオキシソーム増殖剤応答性受容体（ｐｐａｒ）活性化剤、ならびにそれを用いた医薬、サプリメント、機能性食品および食品添加物 | |
| JP5473191B2 (ja) | ペルオキシソーム増殖剤応答性受容体（ｐｐａｒ）活性化剤、ならびにそれを用いた医薬、サプリメント、機能性食品および食品添加物 | |
| Okreglicka | Health effects of changes in the structure of dietary macronutrients intake in western societies | |
| JP2009291187A (ja) | 食生活改善用食品組成物 | |
| JP2013216686A (ja) | ペルオキシソーム増殖剤応答性受容体活性剤および組成物 | |
| Kopcekova et al. | Benefits of sea buckthorn juice consumption in women of productive age with hypercholesterolemia | |
| JPWO2012111643A1 (ja) | アディポネクチン産生促進剤、並びにアディポネクチン産生促進剤を含む医薬組成物、飲食品、及び飼料 | |
| RU2567053C2 (ru) | Состав, ускоряющий продукцию адипонектина | |
| KR20160035522A (ko) | 건강 기능성 칼륨생활죽염의 제조방법 | |
| JP2010059113A (ja) | ペルオキシソーム増殖剤応答性受容体活性剤および組成物 | |
| JP7185990B2 (ja) | アディポネクチン分泌促進剤、脂肪前駆細胞分化促進剤並びにそれらを含む医薬組成物、食品及び飼料 | |
| JP5080813B2 (ja) | メタボリックシンドローム改善剤、ならびにそれを含む医薬、サプリメント、機能性食品および食品添加物 | |
| JP5064036B2 (ja) | メタボリックシンドローム改善剤、ならびにそれを含む医薬、サプリメント、機能性食品および食品添加物 | |
| JPWO2004045632A1 (ja) | ペルオキシソーム増殖剤応答性受容体リガンド剤 | |
| JP2011173813A (ja) | ＰＰＡＲα発現促進剤 | |
| US20190314439A1 (en) | Method for suppressing obesity or development of obesity | |
| JP5346624B2 (ja) | Ｐｐａｒ活性化剤 | |
| JP2012224601A (ja) | 小豆煮汁抽出物を含む脂質代謝改善剤 | |
| KR20110113080A (ko) | 은어 단백질 및 펩타이드를 함유하는 항염증 활성용 조성물 및 추출방법 | |
| JP2009286729A (ja) | アディポネクチン産生促進剤 | |
| JP2012153625A (ja) | 糖尿病予防・治療剤 | |
| Han et al. | Biocellulose reduces body weight gain of rats fed high-fat diet | |
| JP2007246471A (ja) | 血中中性脂肪上昇抑制剤およびその製造方法 | |
| Refaat et al. | Effect of Garlic and Mackerel Fish on Rats Suffering From Obesity | |
| KR20160058363A (ko) | 삼채뿌리 추출물을 유효성분으로 포함하는 골 성장 촉진용 조성물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080516 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080516 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110707 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110812 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20111027 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20111220 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20120322 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120622 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20120710 |
|
| A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20120914 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140725 |